Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille Nord de France, Lille, France.
J Enzyme Inhib Med Chem. 2010 Apr;25(2):158-71. doi: 10.3109/14756360903169485.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), two protein tyrosine kinases, are involved in pathological disorders and the progression of different types of carcinomas. Concomitant inhibition of both tyrosine kinase activities appears to be an attractive target for cancer chemotherapy. A series of new quinazoline derivatives substituted by amide, urea, or carbamic acid ester groups have been synthesized. The biological activities of these new compounds have been evaluated for their enzyme inhibition and antiproliferative activities.
表皮生长因子受体（EGFR）和血管内皮生长因子受体-2（VEGFR-2）是两种蛋白酪氨酸激酶，它们参与病理紊乱和不同类型的癌的进展。同时抑制这两种酪氨酸激酶活性似乎是癌症化疗的一个有吸引力的靶点。一系列新的喹唑啉衍生物被酰胺、脲或碳酸酯基团取代已经被合成。这些新化合物的生物活性已经通过其酶抑制和抗增殖活性进行了评估。
